Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock OptionsZacks Investment Research • 01/28/21
Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in CDKL5 Deficiency Disorder (CDD)Business Wire • 01/13/21
Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C.Business Wire • 01/06/21
Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology IndexBusiness Wire • 12/21/20
Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on TuesdayThe Motley Fool • 12/08/20
Marinus Pharmaceuticals Announces Pricing of $70 Million Public Offering of Common StockBusiness Wire • 12/08/20
Marinus Pharmaceuticals Announces Underwritten Public Offering of Common StockBusiness Wire • 12/07/20
Marinus Pharmaceuticals Provides Additional Ganaxolone Data During Scientific Exhibit at AES2020 Virtual Annual Meeting and Provides Corporate UpdateBusiness Wire • 12/07/20
Marinus Pharmaceuticals to Host Virtual Investor Event at AES On December 7, 2020Business Wire • 12/02/20
Marinus Pharmaceuticals Announces Four Presentations on Ganaxolone at AES2020 Virtual Annual MeetingBusiness Wire • 11/23/20
Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/10/20
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial ResultsBusiness Wire • 11/09/20
Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2020 Financial Results on November 9, 2020Business Wire • 10/20/20
Marinus Pharmaceuticals Participates in Upcoming Investor Healthcare ConferencesBusiness Wire • 10/19/20
Marinus Provides Corporate Update on Phase 3 RAISE Trial in Status Epilepticus (SE)Business Wire • 09/24/20